Elder Care

Experimental antiplatelet compound for acute stroke shows promise

An experimental compound inhibited clot formation without increased bleeding, a common side effect of current anticlotting therapies, in a phase I study. First-in-human study shows the anticlotting drug was well-tolerated without serious safety concerns in healthy volunteers. Next-phases will gauge effectiveness and safety in patients with acute ischemic strokes.

Related posts

Electrophysiological sign of cerebral infarction identified


Heart surgery: To have or not to have…your left atrial appendage closed


Single injection alleviates chemotherapy pain for months in mice